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MitochondriaDuring chronic kidney disease (CKD), drug metabolism is affected leading to changes in drug disposition. Further-
more, there is a progressive accumulation of uremic retention solutes due to impaired renal clearance. Here, we in-
vestigated whether uremic toxins can inﬂuence the metabolic functionality of human conditionally immortalized
renal proximal tubule epithelial cells (ciPTEC) with the focus on UDP-glucuronosyltransferases (UGTs) and mito-
chondrial activity. Our results showed that ciPTEC express a wide variety of metabolic enzymes, including UGTs.
These enzymes were functionally active as demonstrated by the glucuronidation of 7-hydroxycoumarin (7-OHC;
Km of 12±2 μM and a Vmax of 76±3 pmol/min/mg) and p-cresol (Km of 33±13 μM and a Vmax of 266±
25 pmol/min/mg). Furthermore, a wide variety of uremic toxins, including indole-3-acetic acid, indoxyl sulfate,
phenylacetic acid and kynurenic acid, reduced 7-OHC glucuronidation with more than 30% as compared with con-
trols (pb0.05), whereas UGT1A and UGT2B protein expressions remained unaltered. In addition, our results
showed that several uremic toxins inhibited mitochondrial succinate dehydrogenase (i.e. complex II) activity
with more than 20% as compared with controls (pb0.05). Moreover, indole-3-acetic acid decreased the reserve
capacity of the electron transport system with 18% (pb0.03). In conclusion, this study shows that multiple uremic
toxins inhibit UGT activity andmitochondrial activity in ciPTEC, thereby affecting themetabolic capacity of the kid-
ney during CKD. Thismayhave a signiﬁcant impact ondrug anduremic retention solute disposition in CKDpatients.
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Renal function is an important aspect in drug clearance and it is wide-
ly known that drug disposition is altered in patients with chronic kidney
disease (CKD) [1–3]. These changes in pharmacokinetics are partially due
to a decreased glomerular ﬁltration and tubular secretion. Another hall-
mark of CKD is the accumulation of potentially toxic solutes that are
normally excreted via the urine. These uremic toxins can cause a multi-
tude of pathologies, including renal ﬁbrosis, anemia, bone disorders and
cardio-vascular disease [4,5]. Currently, more than 110 uremic toxins
are known, divided into three distinct classes based on their physico-
chemical properties: the small water-soluble compounds, the middle
molecules and the protein-bound solutes [5,6]. The latter group of
retention solutes are actively secreted by the healthy kidney and are dif-
ﬁcult to eliminate using current dialysis strategies [7]. Since protein-
bound uremic toxins accumulate during renal failure it could be argued
that these compounds affect drug metabolism in CKD patients by
interactingwith renal enzymes. Many drugs commonly used in the clinic
are metabolized by phase II enzymes, which catalyze conjugation reac-
tions, including sulfation, acetylation and glucuronidation [8]. Several
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via phase II metabolism is changed in CKD patients. For instance,
a decreased glucuronidation of metoclopramide, chloramphenicol,
p-aminobenzoic acid, zidovudine and morphine have been reported in
patients with chronic renal failure (CRF) [9–14]. Moreover, the acetyla-
tion of isoniazid is reduced in CKD patients [15]. However, little infor-
mation is available about the mechanism underlying the observed
decrease in phase II metabolism during renal failure.
UDP-glucuronosyltransferases (UGT) are an important class of phase
II enzymes that catalyze the conjugation of glucuronic acid tomany xeno-
biotics, environmental pollutants and endogenous compounds [16,17].
Next to drugs, uremic retention solutes are also prone to glucuronidation,
and at least two glucuronides have been identiﬁed in uremic biological
ﬂuids, p-cresyl glucuronide and indoxyl glucuronide [18–20]. UGTs are
expressed in several organs including the liver, gastro-intestinal tract
and kidney, and to date 19 human UGT proteins have been identiﬁed
[21,22]. Due to the relative abundance of the essential cofactor UDP-
glucuronic acid (UDPGA), glucuronidation is themost prevalent conjuga-
tion reaction and under normal metabolic conditions, the supply of
UDPGA is not rate-limiting for this process [23]. Yet, during excessive gly-
cogenesis or under altered redox conditions, UGT activity is impaired
[23,24]. After the liver, UGT activity is highest in the kidney, emphasizing
the pivotal role of this organ in facilitating xenobiotic clearance via
glucuronidation [8,25]. Previously, Yu et al. demonstrated that UGT
expression and activity were down-regulated in the liver and kidney of
5/6 nephrectomized rats. However, this effect was also observed in con-
trol pair-fed rats and was possibly due to a decreased food intake [26].
Thus, the repercussions of CKD on UGTs remain to be elucidated.
In the present study, conditionally immortalized human renal proxi-
mal tubule epithelial cells (ciPTEC) were used to investigate the impact
of multiple uremic toxins on renal UGT activity. Our results show that
ciPTEC express a broad array of drug metabolism enzymes, similar to
human kidney. Furthermore, UGT proteins were functionally active in
ciPTEC, as demonstrated by 7-hydroxycoumarin (7-OHC) and p-cresol
glucuronidation. Uremic toxins inhibited the glucuronidation of 7-OHC
without affecting UGT1A and UGT2B protein expression, indicating a re-
duction in enzyme activity. Moreover, exposure of ciPTEC to uremic
toxins caused a reduction in mitochondrial succinate dehydrogenase
activity and in the maximum capacity of the oxidative phosphorylation
(OXPHOS) system, which could explain the observed inhibitory effect
of uremic toxins on glucuronide formation. These results present a
novel pathway via which uremic retention solutes affect the metabolic
capacity of the kidney and are likely involved in altering drugmetabolism
by glucuronidation in CKD patients.
2. Materials and methods
2.1. Chemicals
All chemicals were obtained from Sigma (Zwijndrecht, The
Netherlands) unless stated otherwise. Stock solutions of uremic
toxins were prepared as described by Cohen et al., [27] and were
stored at−20 °C. Both p-cresyl sulfate and phenyl sulfate were synthe-
sized as a potassium salt as described previously [28]. P-cresyl glucuro-
nide was produced from glucuronyl-trichloroacetimidate and p-cresol
using the method previously described by Van der Eycken et al. [29].
2.2. Cell culture
The ciPTEC line was generated as previously described by Wilmer et
al. [30]. The cells were cultured in ciPTEC medium containing phenol
red free DMEM/F12medium (Gibco/Invitrogen, Breda, TheNetherlands)
supplemented with 10% (v/v) fetal calf serum (FCS; MP Biomedicals,
Uden, The Netherlands), insulin (5 μg/ml), transferrin (5 μg/ml), se-
lenium (5 ng/ml), hydrocortisone (36 ng/ml), epithelial growth
factor (10 ng/ml), and tri-iodothyronine (40 pg/ml) at 33 °C in a5% (v/v) CO2 atmosphere. Propagation of cells was maintained by
subculturing the cells at a dilution of 1:3 to 1:6 at 33 °C. For exper-
iments, cells were cultured at 33 °C to 40% conﬂuency, followed by
maturation for 7 days at 37 °C. Experiments were performed on the
cells between passages 30 and 40.
2.3. Quantitative PCR array
To study the gene expression of drug metabolism enzymes, ciPTEC
were cultured and differentiated cells (7 days at 37 °C) were harvested.
Total RNA was isolated using an RNeasy Mini kit (Qiagen, Venlo, The
Netherlands) according to the manufacturer's recommendations. Subse-
quently, cDNA was generated using the Omniscript RT-kit (Qiagen)
according to the manufacturer's recommendations. Following cDNA-
synthesis, RT2 Proﬁler PCR arrays (drug metabolism: phase I and phase
II enzymes; Qiagen) were performed according to the manufacturer's
recommendations, using a CFX96 Real-Time PCR detection system
(Bio-rad, Veenendaal, The Netherlands). Quantiﬁcation of gene expres-
sion was performed using the CFX96 system software (Bio-rad) and the
web-based PCR array data analysis software (Qiagen). GAPDH was used
as housekeeping gene, and relative expression levels were calculated as
percentage as compared with GAPDH (100%).
2.4. Western blotting
To study the protein expression of UGT1A and UGT2B, ciPTEC were
cultured and exposed to 0–2 mM of different uremic toxins for 48 h.
After treatment, cells were harvested using RIPA buffer containing 1%
(v/v) Igepal CA630, 0.5% (v/v) Nadeoxycholate, 0.1% (w/v) SDS, 0.01%
(w/v) phenylmethane sulphonylﬂuoride, 3% (v/v) aprotinin and
1 mM Na-orthovanadate. Total protein (50 μg) was separated via
SDS/PAGE using 10% (w/v) gels and blotted onto nitrocellulose
membranes using the iBlot dry blotting system (Invitrogen). After-
wards, the membrane was blocked using Odyssey Blocking Buffer,
(1:1 diluted with PBS; LI-COR Biosciences, Lincoln, NE, USA) during
1 h at RT. The membrane was then incubated overnight at 4 °C with
rabbit polyclonal UGT1A or UGT2B antibody (1:200; both Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA). Mouse monoclonal β-actin
antibody (1:10,000; Sigma) was simultaneously incubated to serve
as a protein loading control. Antibodies were diluted in Odyssey
Blocking Buffer containing 0.1% (v/v) Tween-20. Afterwards, the
membrane was thoroughly washed three times during 10 min with
PBS containing 0.1% (v/v) Tween-20. The secondary antibodies,
goat-α-mouse Alexa Fluor 680 (1:20,000; Invitrogen) and goat-α-rabbit
IRDye 800 (1:20,000; Rockland, Gilbertsville, PA, USA), were incubated
for 1 h at RT in Odyssey Blocking Buffer containing 0.1% (v/v) Tween-20
and 0.01% (w/v) SDS. The membrane was thoroughly washed, as
described above, and then scanned using the Odyssey Infrared Imaging
System (LI-COR Biotechnology). Intensity of the protein bands was quan-
tiﬁed using the Odyssey Application software version 2.1.
2.5. Confocal microscopy
Cellular localization of UGT1A and UGT2B proteins was investigated
using confocal microscopy. ciPTEC were seeded on 12-well Corning
Costar Transwell Permeable Supports (type 3460, Corning Costar, NY,
USA). Before seeding, the supports were coated with 50 μg/ml collagen
type IV for 2 h at 37 °C. Subsequently, supportswerewashedwithHBSS
buffer (Gibco) and cellswere seeded at a density of 1.33×105 cells/cm2.
Followingmaturation, as described above, cellswerewashedwithwash
solution (4% (v/v) FCS in HBSS) and ﬁxed for 5 min with 2% (w/v)
paraformaldehyde in HBSS. Next, cells were permeabilized for 10 min
in HBSS with 0.3% (v/v) Triton and aspeciﬁc epitopes were blocked for
30 min with blocking buffer (2% (v/v) FCS, 0.5% (w/v) bovine serum
albumin and 0.1% (v/v) Tween-20 in HBSS). Subsequently, the cells
were incubated overnight at 4 °C with rabbit polyclonal UGT1A or
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using dynamic conditions. Afterwards, cells were incubated for 30 min
with the secondary antibody goat-α-rabbit Alexa568 (1:200, Molecular
Probes, Invitrogen). Subsequently, ciPTEC were incubated for 1 h with a
mouse monoclonal antibody against the tight junction protein ZO-1
(1:50 in blocking buffer, Invitrogen, CA, USA). Next, the cells were simul-
taneously incubated for 30 min with goat-α-mouse Alexa488 (1:200,
Molecular Probes, Invitrogen) and DAPI nucleic acid stain (300 nm,
Molecular Probes, Invitrogen). The slides were then mounted using
Fluorescent Mounting Medium (DakoCytomation, Dako Netherlands
b.v., Heverlee, Belgium). Between all incubation steps the cells were
washed with wash solution. Fluorescence was examined using the
Olympus FV1000 Confocal Laser Scanning Microscope (Olympus,
UK) and images were captured using the Olympus software FV10-ASW
version 1.7.2.6. High-performance liquid chromatography (HPLC)
HPLC was used to measure UGT activity via the glucuronidation of
7-hydroxycoumarin (7-OCH), as described previously, [31] and p-cresol.
To determine enzyme kinetics, ciPTEC were exposed to 7-OCH or p-
cresol dissolved in HBSS at 37 °C and 4 °C (as negative control) using
different concentrations (0–500 μM) and different incubation times
(0–5 h). When used, β-glucuronidase from Helix pomatia was added
1 h prior to incubation with 7-OHC (50 μM for 3 h). In addition, UGT
activity was also determined following exposure to uremic toxins for
48 h. Following treatment, ciPTEC were incubated with 10 μM 7-OCH
for 3 h at 37 °C. Before chromatography an aliquot of culture medium
was collected and centrifuged at 12,000×g for 3 min and 50 μl of the
supernatant was injected into the HPLC-system (Spectra-Physics
Analytical, Spectrasystem SCM400). To measure 7-OCH and 7-OCH
glucuronide (7-OCHG) theHPLCwas equippedwith a C18HPLC column
(GraceSmart RP 18 5u 150×4.6 mm; Grace, Breda, The Netherlands).
Separation was performed at a ﬂow rate of 1 ml/min with eluent A
(95% (v/v) H2O, 5% (v/v) methanol and 0.2% (v/v) acetic acid) and elu-
ent B (50% (v/v) H2O, 49% (v/v) acetonitrile and 1% (v/v) tetrahydrofu-
ran) under the following gradient conditions: 0–3 min, 80–50% eluent
A; 3–8 min, 50% eluent A; 8–9 min, 50–80% eluent A; 9–14 min, 80%
eluent A. The compounds were detected at a wavelength of 316/
382 nm. For the detection of p-cresyl sulfate and p-cresyl glucuronide,
chromatography was performed on a C18 HPLC column (GraceSmart
RP 18 5u 150×4.6 mm) with eluent A (95% (v/v) 50 mM KH2PO4 (pH
3.0) and 5% (v/v) acetonitrile) and eluent B (50 mM KH2PO4 (pH 3.0),
methanol and acetonitrile in a 1:1:1 ratio) using the following gradient:
0–15 min, 100–20% eluent A; 15–16 min, 20–100% eluent A; 16–21 min,
100% eluent A. The ﬂow rate was 1 ml/min and the p-cresol metabolites
were detected at a wavelength of 220 nm. Standards of the compounds
were also run in order to quantify the amount of metabolites found in
the samples. Acquired data were processed with PC1000 software
(Spectrasystem).2.7. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) assay
Mitochondrial succinate dehydrogenase activity was assessed using
the MTT assay. ciPTEC were cultured in a 96 well culture plate and ex-
posed to 1 mM or 2 mM of uremic toxins for 48 h. Next, medium was
removed and 20 μl preheated (37 °C) MTT-solution (5 mg 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide/ml ciPTEC
medium) was added and incubated for 4 h at 37 °C. Afterwards, MTT-
solution was removed, followed by the addition of 200 μl DMSO to dis-
solve produced formazan crystals. The extinction of the solution was
measured at 570 nm using a Benchmark Plus Microplate Spectropho-
tometer (Bio-rad).2.8. Flow cytometry
In this study, ﬂow cytometry was used to study ciPTEC morphology
and viability. Cells were cultured in 12-well culture plates and treated
for 48 h with 2 mM of uremic toxins. After incubation, cells were
harvested using trypsin-EDTA and centrifuged at 600×g during 5 min.
Subsequently, supernatant was removed and the cell pellet was
resuspended in 100 μl PBS containing 4% (w/v) paraformaldehyde and
0.1% (v/v) saponin followed by 10 min incubation on ice. Subsequently,
sampleswere centrifuged (600×g for 5 min) and resuspended in 100 μl
PBS. Samples were acquired on a BD FACSCalibur (Becton Dickinson,
Breda, The Netherlands). Analysis was performed using Flow Jo soft-
ware (TreeStar, Ashland, USA), gating on live cells.2.9. High-resolution respirometry
Cells were cultured in T25 culture ﬂasks and treated for 48 h with
2 mM indole-3-acetic acid. Subsequently, cells were harvested using
trypsin-EDTA and centrifuged at 1500×g during 5 min. Afterwards, the
supernatant was removed and the cell pellet was resuspended in ciPTEC
medium to obtain a suspension of approximately 1×106cells/ml. Two
milliliters of the cell suspension was used to measure cellular oxygen
consumption. Oxygen consumption was measured at 37 °C using polar-
ographic oxygen sensors in a two-chamber Oxygraph (Oroboros Instru-
ments, Innsbruck, Austria) using an established protocol [32]. The cells
were allowed to respire at basal level for at least 10 min until the ﬂux
was stable, representing routine respiration (R). Next, leak respiration
(L) was determined by addition of the speciﬁc mitochondrial ATP
synthase inhibitor oligomycin A (omy; 2.5 μM). Then, maximal ETS
capacity (E) was quantiﬁed using increasing concentrations of the
mitochondrial uncoupler p-triﬂuoromethoxy carbonyl cyanide phenyl
hydrazone (FCCP; 2.5 μM maximal concentration). Finally, non-
mitochondrial respiration (ROX) was assessed by adding a maxi-
mal (0.5 μM) concentration of the speciﬁc mitochondrial complex
I inhibitor rotenone (ROT) followed by the Complex III inhibitor
antimycin A (AA; 2.5 μM).2.10. Kinetic analysis and statistics
Statistics were performed using GraphPad Prism 5.02 via one-way
analysis of variance (ANOVA) followedbyDunnett'sMultiple Comparison
Test or an unpaired t test. Differences between groupswere considered to
be statistically signiﬁcant when pb0.05. The software was also used to
perform linear and nonlinear regression analysis (Michaelis–Menten)
and correlation analysis (Spearman).3. Results
3.1. Selection of uremic toxins
In our study, 13 uremic solutes were selected containing one
water-soluble solute (oxalate, Ox) and 12 protein-bound solutes. The
latter group contained 4 tryptophan metabolites (indoxyl sulfate, IS;
indole-3-acetic acid, I3A; kynurenic acid, KA; and quinolinic acid, QA),
six phenols (phenylacetic acid, PHA; phenyl glucuronide, PHG; phenyl
sulfate, PHS; p-cresol, pC; p-cresyl sulfate, pCS; and p-cresyl glucuronide,
pCG), one hippurate (hippuric acid, HA) and one polyamine (putrescine,
Pu). Moreover, amix of several uremic toxins (Mix)was used, consisting
of putrescine, oxalate, indoxyl sulfate and p-toluenesulfonic acid, a
previously described phenolic model compound (1:1:1:1) [33]. This
speciﬁc mix was chosen because it contained different classes of solutes,
of which the stock solutions were all prepared in the same solvent
(e.g.milli-Q).
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Extrahepatic glucuronidation occurs mainly in the kidney and UGT
expression and activity were demonstrated in both human and rat pri-
mary proximal tubule cells [8,34,35]. We used a recently established
human renal proximal tubule cell line, [30,36] in which phase I and
phase II drug metabolism enzyme expression levels were studied,
with an emphasis on the class of UGT enzymes. A complete overview
of the drug metabolism enzyme gene expression in ciPTEC is provided
in Fig. S1. This ﬁgure clearly demonstrates that ciPTEC express a broad
range of drug metabolism enzymes, including cytochrome p450 (CYP),
sulfotransferase (SULT) and glutathione S-transferase (GST) enzymes,
next to members of the UGT family. Fig. 1A shows that the gene expres-
sion of 18 UGTs was detected in ciPTEC of which UGT1A1, 1A9, 2B7,
2B10 and 2B28 were most abundantly expressed compared with
GAPDH, with a relative expression of 11%, 2143%, 16%, 145% and 9%,Fig. 1. Expression of UGTs in ciPTEC. (A) Differentiated ciPTEC were harvested and total
mRNA was isolated. Afterwards, cDNA was synthesized and UGT gene expression was
studied using a qPCR array. Relative expression was calculated using the household
gene GAPDH (100%). Bars represent mean±SEM of two experiments. (B–C) UGT1A and
UGT2B protein expression was studied by Western blotting. Proteins were separated via
SDS/PAGE and blotted onto nitrocellulose membranes. Lysates of HEK293 cells were
used as a negative control and homogenates from human kidney (HuKid) were used as
positive control. Both UGT1A and UGT2B were detected at 68 kD. (D–E) Confocal micros-
copywas used to study intracellular localization of UGTs in ciPTEC. Followingmaturation,
cells were ﬁxed and permeabilized and subsequently stained using an antibody against
UGT1A or UGT2B and ZO-1. Detection was performed using Alexa568 for UGTs (red)
and Alexa488 for ZO-1 (green) labeled secondary antibodies. Nucleus was stained with
DAPI (blue). (B–E) Representative images of two independent experiments.respectively. Furthermore, using Western blotting UGT1A and 2B fam-
ily members were detected in ciPTEC, with the predicted molecular
weight of the enzymes (approximately 68 kD; Fig. 1B–C). Protein
expression of the enzymes was also demonstrated in human kidney
lysates, whereas their expression was absent in human embryonic kid-
ney (HEK293) cells. Glucuronide formation occurs in the cytosol, and
confocal microscopy demonstrated that both UGT1A and 2B enzymes
exhibit cytosolic localization in ciTPEC (Fig. 1D–E). Moreover, expres-
sion of tight junction protein 1 (ZO-1) revealed that ciPTEC form
tight monolayers and that the cells maintain their epithelial character-
istics during culturing.
To determine whether the UGTs were enzymatically active, a
glucuronidation assay was performed using 7-OHC as a substrate. A
concentration-dependent formation of 7-OHC glucuronide was ob-
served (Fig. 2A), and curve ﬁtting revealed an apparent Km of 12±
2 μM and a Vmax of 76±3 pmol/min/mg. Glucuronidation was demon-
strated to be linear up to 5 h (Fig. 2B). Furthermore, as depicted in
Fig. 2A and 2B, 7-OHC metabolism was completely absent at 4 °C,
indicating enzyme-dependent conjugation. Glucuronidation of 50 μM
7-OHC was concentration-dependently inhibited by β-glucuronidase
with an approximate IC50 value of 50 U/ml, as demonstrated in Fig. 2C.
3.3. Uremic toxins decrease UGT activity
Next, it was investigatedwhether exposure of ciPTEC to uremic toxins
could inﬂuence 7-OHC glucuronidation Fig. 3 shows that a myriad
of uremic toxins belonging to three different physico-chemical classes,
viz. tryptophan metabolites, phenols and water-soluble compounds,
concentration-dependently inhibited the glucuronidation of 7-OHC.
Kynurenic acid, indole-3-acetic acid, phenylacetic acid and a mixture
of uremic toxins most potently inhibited UGT activity (Fig. 3A–C). At
the highest concentration, these toxins decreased glucuronide forma-
tion by 52%, 44%, 36% and 50%, respectively. In addition, at the same
concentration, indoxyl sulfate, phenyl sulfate, oxalate, putrescine and
hippuric acid inhibited the formation of 7-OHCG by 32%, 30%, 16%,
18% and 32%, respectively. In contrast, quinolinic acid and phenyl glucu-
ronide did not affect 7-OHC metabolism.
A decline in enzyme activity is often secondary to a decrease in
protein expression, therefore, the impact of uremic toxins on UGT
expression was examined. Exposure of ciPTEC to none of the different
toxins reduced UGT1A and UGT2B protein expression with more than
15%, with both tested concentrations, compared to control. A represen-
tative sample of toxins is shown in Fig. 4, and the other toxins in Fig. S2.
3.4. P-cresol metabolism and impact on glucuronidation
To further investigate the mode of inhibition, ciPTEC were exposed to
p-cresol, which can be metabolized to both p-cresyl sulfate and p-cresyl
glucuronide [37]. Fig. 5A shows that p-cresol is indeed conjugated to
glucuronic acid in ciPTEC and a concentration-dependent formation of
p-cresyl glucuronide is demonstrated with a calculated Km of 33±
13 μM and a Vmax of 266±25-pmol/min/mg. In contrast, ciPTEC did
not metabolize p-cresol to p-cresyl sulfate (data not shown), despite
the expression of multiple sulfotransferases, the enzymes that catalyze
sulfation reactions (Fig. S1). Furthermore, HPLC revealed that p-cresol
inhibited 7-OHCG formation by 72% (Fig. 5B). Yet, both p-cresol metabo-
lites also inhibited UGT activity with approximately 20%.
3.5. Uremic toxins inhibit mitochondrial metabolism
Reduction of MTT is mainly dependent on mitochondrial succinate
dehydrogenase activity [38]. Our results indicate that the majority of
the toxins tested (e.g. putrescine, oxalate, indoxyl sulfate) did not
signiﬁcantly decrease MTT reduction with more than 15% compared
to control (Fig. S3). Yet, p-cresol, p-cresyl sulfate and p-cresyl glucu-
ronide signiﬁcantly reduced mitochondrial succinate dehydrogenase
Fig. 2. UGTs are functionally active. HPLC was used to study UGT activity via 7-OHC
glucuronidation. Cells were incubated with 7-OHC (0–500 μM) for 0–5 h at 37 °C
(●) or 4 °C (negative control; ■). To further demonstrate speciﬁcity of the HPLC meth-
od, cells were incubated with 50 μM 7-OHC for 3 h in the presence of β-glucuronidase
(0–1000 u/ml). (A) Concentration-dependent formation of 7-OHCG. (B) Time curve of
7-OHC glucuronidation. (C) β-glucuronidase inhibits glucuronide formation. Standards
of 7-OHCGwere also analyzed in order to quantify the amount of glucuronide found in the
samples. Acquired HPLC data were processed with PC1000 software (Spectrasystem).
Nonlinear and linear regression analyses were performed using Graphpad Prism 5.02.
Results are presented as mean±SEM of three independent experiments performed in
triplicate.
Fig. 3. Uremic toxins inhibit 7-OHC glucuronidation. Impact of uremic toxin exposure on
7-OHC glucuronidation was studied using HPLC. Cells were exposed for 48 h to ciPTEC
medium (gray bar), 1 mM (white bars) or 2 mM (black bars) of several uremic toxins be-
longing to three different physico-chemical classes: (A) tryptophanmetabolites, (B) phenols
and (C)water-soluble compounds. Following treatment, ciPTECwere incubated for 3 hwith
10 μM 7-OHC. Afterwards, an aliquot of culture mediumwas collected and injected into the
HPLC-system. Standards of 7-OHCG were also analyzed in order to quantify the amount of
glucuronide found in the samples. AcquiredHPLCdatawereprocessedwith PC1000 software
(Spectrasystem). Statistical analysis was performed via one-way ANOVA followed by
Dunnett's Multiple Comparison Test for each toxin. Results are presented as mean±
SEM of three experiments performed in duplicate or triplicate. *=pb0.05 compared
with control. HA, hippuric acid; I3A, indole-3-acetic acid; IS, indoxyl sulfate; KA, kynurenic
acid; M, medium; Mix, uremic toxin mix; Ox, oxalate; PHG, phenyl glucuronide; PHS,
phenyl sulfate; PHA, phenylacetic acid; Pu, putrescine; QA, quinolinic acid.
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toxins that most potently inhibited UGT activity (i.e. indole-3-acetic
acid, phenylacetic acid and amixture of uremic toxins) also signiﬁcantly
decreased MTT reduction at the highest concentration by 28%, 26% and
33%, respectively. Moreover, we observed a signiﬁcant correlation be-
tween the two parameters studied, with a calculated Spearman r of
0.69 (pb0.005; Fig. 6B). Since the MTT assay is often used to study cell
viability, we aimed to conﬁrm that the observed correlation was not
due to the induction of cell death by uremic toxins. Flow cytometry re-
vealed that exposure of ciPTEC to the solutes that had the most pro-
nounced impact on cellular and mitochondrial metabolism did not
affect cell morphology nor the percentage of living cells as compared
with untreated cells (Fig. S4).3.6. Inhibition of mitochondrial respiration by indole-3-acetic acid
Mitochondrial succinate dehydrogenase plays an essential role in the
electron transfer chain and the tricarboxylic acid cycle (i.e. citric acid
cycle) [39]. Therefore, we investigated the impact of indole-3-acetic acid
on the OXPHOS system, since this solute had the most profound effect
on both 7-OHC glucuronidation and MTT reduction. High-resolutionrespirometry revealed that basalmitochondrial respiration (R; ROUTINE),
electron transport that was not coupled to ATP production (L; LEAK) and
non-mitochondrial respiration (ROX; residual oxygen consumption) was
not compromised by indole-3-acetic acid (Fig. 7A–B), further supporting
the impression that uremic toxins did not induce cell death in ciPTEC. In
contrast, the maximum capacity of the electron transport system (E;
ETS) was reduced from 221±21 pmol/s ∙106 cells in untreated cells to
182±17 pmol/s ∙106 cells in ciPTEC exposed to indole-3-acetic acid,
indicating that treatment caused a reduction in the reserve capacity
for energy production. Fig. 7C shows that exposure of the cells to
indole-3-acetic acid resulted in a signiﬁcantly increased netRoutine/ETS
ratio, with a 1.3 fold change. This signiﬁes that a higher proportion of
the maximum capacity of the OXPHOS system is activated to drive ATP
synthesis, and implies that ciPTEC exposed to uremic toxins have a lim-
ited ability to supply energy for other cellular processes, such as enzy-
matic activity.
Fig. 4. UGT1A and UGT2B protein expression is not affected by uremic toxins. UGT1A and UGT2B protein expression was studied via Western blot. Cells were exposed for 48 h to ciPTEC
medium (gray bar), 1 mM (white bars) or 2 mM (black bars) of several uremic toxins. (A/C) Afterwards cells were lysed and proteins were separated via SDS/PAGE and blotted onto nitro-
cellulose membranes. Both UGT1A and UGT2B were detected at 68 kD. (B/D) Fluorescence of the speciﬁc protein bands was determined using the Odyssey Infrared Imaging System. Bars
representmean±SEMof the UGT band intensities corrected for β-actin from 3 independent experiments. IS, indoxyl sulfate; M,medium;Mix, uremic toxinmix; Ox, oxalate; Pu, putrescine.
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This study reports for the ﬁrst time that multiple uremic toxins
directly inhibit the function of an important class of phase II drug metab-
olism enzymes, namely UGTs, in human renal proximal tubule cells.
Our results showed that uremic toxin-induced UGT inhibition was inde-
pendent of an effect on protein expression, and inhibition seemed toFig. 5. P-cresol glucuronidation and impact on UGT activity by cresols. (A) HPLCwas used
to study p-cresol glucuronidation. Cells were incubated with p-cresol (0–500 μM) for 1 h
at 37 °C (●) or 4 °C (negative control; ■). (B) Cells were exposed for 48 h to ciPTEC
medium (gray bar), 1 mM (white bars) or 2 mM (black bars) of p-cresol or the metabo-
lites. Following treatment, ciPTECwere incubated for 3 hwith 10 μM7-OHC. After incuba-
tion with p-cresol or 7-OHC, an aliquot of culture mediumwas collected and injected into
theHPLC-system. Standards of the compoundswere also analyzed in order to quantify the
amount of metabolites found in the samples. Acquired HPLC data were processed with
PC1000 software (Spectrasystem). Nonlinear analysis was performed using Graphpad
Prism 5.02 and statistical analysis was performed via one-way ANOVA followed by
Dunnett's Multiple Comparison Test for each toxin. Results are presented as mean±
SEM of three independent experiments performed in duplicate or triplicate. *=pb0.05
compared with control. M, medium; pC, p-cresol; pCG, p-cresyl glucuronide; pCS,
p-cresyl sulfate.occur in both a competitive (e.g. p-cresol) and non-competitive fashion
(e.g. p-cresyl sulfate). It is likely that most uremic solutes act as non-
competitive inhibitors of UGT activity, since the majority of these com-
pounds are end-products of endogenous metabolism.
To further unravel themode of inhibition, mitochondrial respiration
was studied and the results indicated that indole-3-acetic acid reduced
the reserve capacity of the electron transport system. This ﬁnding
provides more insight into the mechanism by which uremic toxins
possibly inhibit UGT activity. As stated before, glucuronide formation
is dependent on the availability of UDPGA, the donor of the glucuronide
moiety [23]. UDPGA is formed fromUDP-glucose by UDP-glucose dehy-
drogenase using nicotinamide adenine dinucleotide (NAD+), a coen-
zyme that plays an important role in energy metabolism [40]. In the
mitochondria, enzymes of the citric acid cycle reduce NAD+ to NADH.
Subsequently, NADH is oxidized by complex I of the electron transport
chain during OXPHOS-mediated ATP production, resulting in the con-
version of NADH toNAD+ [40]. Therefore, we postulate that a reduction
in the activity of the mitochondrial electron transport chain induced by
uremic toxins, as demonstrated in this study, caused a drop in NAD+
levels and, consequently, led to depletion of UDPGA, thereby decreasing
UGT-mediated metabolism.
De novo synthesis of NAD+ in mammals is dependent on trypto-
phan metabolism via the kynurenine pathway [40]. Dietary trypto-
phan is converted to kynurenine by tryptophan 2,3-dioxygenase
and indoleamine 2,3-dioxygenase, which are both considered the
rate-limiting steps in this pathway [40,41]. Kynurenine can, subse-
quently, be metabolized to kynurenic acid by kynurenine aminotrans-
ferase or, via several other enzymatic steps, to quinolinic acid [41].
The latter metabolite is used by quinolinic acid phosphoribosyl
transferase to form NAD+. Interestingly, it is known that plasma
tryptophan levels are signiﬁcantly diminished in CKD patients [42].
Furthermore, Fukuwatari et al. reported that NAD (NAD++NADH)
concentrations were decreased in the liver, kidney and blood of
rats with adenine-induced renal failure [43]. Thus, it is likely that
UDPGA levels are reduced in patients with CKD due to altered trypto-
phan metabolism, resulting in a reduced UGT activity.
To our knowledge, this is the ﬁrst report to demonstrate the inﬂu-
ence of uremic toxins on mitochondrial metabolism and respiration
in human proximal tubule cells. Previously, Owada et al. demonstrat-
ed that indoxyl sulfate stimulated renal mitochondrial superoxide
production in rats [44]. Dzurik et al. described that hippuric acid re-
duced ammonia production by P-dependent mitochondrial glutamin-
ase in kidney homogenates of acidiﬁed rats [45]. Furthermore, using
isolated rat liver mitochondria, Kitagawa revealed that p-cresol
Fig. 7. Reduction in mitochondrial respiration by indole-3-acetic acid. High-resolution res-
pirometry was used to measure mitochondrial oxygen consumption. Cells were treated for
48 hwith ciPTECmedium (white bar) or 2 mM indole-3-acetic acid (black bar) and oxygen
consumption was measured at 37 °C using polarographic oxygen sensors in an Oxygraph.
(A) Online high-resolution respirometry traces of mitochondrial respiration in a represen-
tative experiment with control (solid line) and indole-3-acetic acid (dashed line) treated
cells. Titrations: ROUTINE (R) respiration (intact cells), omy (LEAK respiration; L), FCCP
(ETS capacity; E), Rot and AA (ROX). (B) Quantiﬁcation of cellular respiration. (C) Quantiﬁ-
cation of cellular respiration corrected for electron transport system capacity. Statistical
analysis was performed via an unpaired t test. Results are presented as mean±SEM of
three experiments performed in duplicate. *=pb0.05 compared with control.
Fig. 6. Inhibitory effect of uremic toxins onMTT reduction. (A) The MTT assay was used to
study the impact of uremic toxins on mitochondrial metabolism. Cells were exposed for
48 h to ciPTEC medium (gray bar), 1 mM (white bars) or 2 mM (black bars) of several
uremic toxins. Afterwards, cells were incubated for 4 h withMTT-medium at 37 °C. Subse-
quently, produced formazan crystalswere dissolved inDMSO and extinctionwasmeasured
at 570 nm. Statistical analysis was performed via one-way ANOVA followed by Dunnett's
Multiple Comparison Test for each toxin. Results are presented as mean±SEM of three
independent experiments performed in triplicate. *=pb0.05 compared with control. I3A,
indole-3-acetic acid; M, medium; Mix, uremic toxin mix; pC, p-cresol; pCG, p-cresyl
glucuronide; pCS, p-cresyl sulfate; PHA, phenylacetic acid. (B) Correlation between UGT
activity andMTT reduction. Cells were exposed for 48 h to 1 mM(○) or 2 mM(▲) of sev-
eral uremic toxins and 7-OHC glucuronidation and MTT reduction were investigated.
Nonparametric Spearman correlation analysis revealed a signiﬁcant association between
the reduction in glucuronidation and mitochondrial dehydrogenase activity when ciPTEC
were treated with 2 mM of uremic toxins (r=0.69; pb0.005). Following exposure to
1 mM of uremic toxins, no signiﬁcant correlation was observed (r=0.48; p=0.07).
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tion [46]. Yet, p-cresol is no longer regarded as a uremic toxin, [37]
and it remains to be elucidated whether its major metabolite,
p-cresyl sulfate, has a similar impact on mitochondrial respiration.
Additionally, Riegel et al. reported that treatment of hepatocytes
with ultraﬁltrates of patients treated with high-ﬂux membrane dia-
lyzer signiﬁcantly diminished MTT reduction [47]. However, the ef-
fect correlated with an increased LDH release, a marker of cell
injury, and the decrease in metabolic activity might have been due
to hepatotoxicity. These ﬁndings, together with our current results,
suggest that uremic toxins might directly inﬂuence mitochondrial ac-
tivity in different organs.
The uremic toxin concentrations used in this study do not always
reﬂect the plasma levels determined in CKD patients, for instance the
highest concentration reported for kynurenic acid is 50 μM, whereas
the maximal uremic concentration for hippuric acid and phenylacetic
acid are 2.6 and 7.7 mM, respectively [48,49]. An overview of the max-
imal uremic concentrations of the solutes used in the present study are
provided in Table S1, and for a detailed description of uremic toxin con-
centrations the interested reader is referred to reviews by the European
Uremic Toxin Work Group [48,50].
Since UGTs are located in the cytosol, enzyme activity depends on
the intracellular levels of substrates rather than substrate concentra-
tions in the blood. Uptake of uremic toxins in renal proximal tubules
is fairly well characterized and shown to be dependent on a widevariety of transport proteins. Both organic anion transporter (OAT) 1
and OAT3, as well as organic anion transporting polypeptide 4C1, play
an important role in the tubular uptake of uremic toxins [51–54]. In addi-
tion, it has been demonstrated that the multi-ligand receptor megalin is
involved in the endocytotic uptake of a speciﬁc group of uremic toxins,
i.e. advanced glycation end products [55]. Previously, Masereeuw et al.
demonstrated that methyl hippuric acids accumulate in the isolated
perfused rat kidney during secretory transport [56,57]. They reported
that 2-methyl hippuric acid levels were 175-times higher in renal tissue
compared to the perfusate and 4-methyl hippuric acid concentrations
were even 600-times higher. Thus, it is likely that intracellular uremic
toxin concentrations are much higher than total plasma concentrations.
Therefore, it is complicated to extrapolate our ﬁndings to the clinical
situation.
The present study demonstrates that UGT1A1, 1A9, 2B7 and 2B28
are highly expressed in ciPTEC, which corroborates previous reports
on proximal tubule cells [21,34]. Lash et al. described that primary
human proximal tubule cells (PTEC) express UGT1A1, 1A6 and 2B7 on
protein level [34]. Furthermore, they postulated that UGT2B7 is the
major UGT isoform present in PTEC cells. In the study from Ohno and
coworkers, gene expression was demonstrated for UGT1A5, 1A6, 1A7,
1A9, 2B4, 2B7 and 2B17 in human kidney tissue, and they reported
that UGT1A9 and 2B7 were most abundantly expressed [21]. Next to
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have RNA expression of phase I enzymes, such as CYP3A4, CYP4A11,
CYP2D6, that have previously been detected in primary PTEC by Lash
et al. [34]. Additionally, the phase II enzymes GSTA4, GSTP, GSTT and
SULT1A3were demonstrated in our current study, as well as in primary
PTEC. Taken together, ciPTEC have a similar phase I and phase II enzyme
expression proﬁle comparedwith primary PTEC, indicating that this cell
line is a suitable model to study extrahepatic drug metabolism. Togeth-
erwith the endogenous expression of renal inﬂux and efﬂux drug trans-
porters, previously described by our group, [30] these data demonstrate
that human ciPTEC is a unique tool to study renal pharmacokinetics.
The majority of studies investigating the effect of renal failure on
drug metabolism focused on CYP enzymes. For instance, Leblond et al.
demonstrated that during CKD, both hepatic protein and gene expres-
sion of CYP2C11, CYP3A1 and CYP3A2 decreased in rats, which correlat-
ed with a decreased metabolism of aminopyrine and erythromycin
[58,59]. The same group also showed that 48 h exposure of HK-2
cells to serum from uremic rats decreased the protein expression of
CYP3A1, suggesting a role for uremic toxins in this process [60]. More-
over, using rat livermicrosomes, Sun et al. described that indoxyl sulfate
and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) di-
rectly inhibited CYP3A-mediated metabolism of erythromycin [61].
With regard to phase II drug metabolism, Simard et al. demonstrated
that N-acetyltransferase (NAT)1 and NAT2 expression decreased in
the liver of CRF rats accompanied by a decrease in NAT2-mediated
N-acetylation of p-aminobenzoic acid [9]. Furthermore, expression of
both NAT1 and NAT2 decreased in rat hepatocytes following exposure
to uremic serum, possibly via the action of parathyroid hormone, a
known uremic toxin [9]. Taken together, there is a clear impact of
uremic solutes on both phase I and phase II drug metabolism.
Hepatic and renal transporters play an important role in xenobiotic
handling. Previously, our group described that several uremic toxins,
includinghippuric acid and indoxyl sulfate, inhibited transport by two im-
portant renal efﬂux transporters, namely breast cancer resistance protein
andmultidrug resistance protein 4 [33]. Huang et al. showed that uremic
plasma, obtained from rats with CRF, inhibited p-glycoprotein-mediated
transport [62]. Moreover, it is demonstrated that CMPF and hippuric
acid inhibited the uptake by the renal uptake transporter OAT3 [51].
The impact of uremic toxins on the functionality of multiple transporters
in those reports, and the inhibition of enzyme activity described in this
study, indicate that the altered drug disposition observed in CKD patients
can be attributed, at least in part, to uremic retention solutes.
In the present study, renal glucuronidation was solely studied in vitro
using the ciPTECmodel, which could differ from in vivometabolism. Gen-
erally, UGT activity is studiedusingmicrosomes isolated from the organ of
interest; however, by using a complete cell model instead ofmicrosomes,
wewere able to unravel the possiblemechanism viawhich uremic toxins
indirectly inﬂuence UGT functionality. Moreover, it is known that there
are species differences in renal glucuronidation [63], which did not ham-
per our study since ciPTEC are of human origin. Another possible draw-
back of the present study is that we studied renal metabolism, while
during CKD, xenobiotics aremetabolizedmainly in the liver and intestine.
However, it is known that both renal and non-renal clearance are affected
in CKD patients [14], therefore we postulate that our results uncovered a
general mechanism viawhich uremic toxins can diminish both renal and
non-renal UGT activity, irrespective of the tissue-speciﬁc UGT expression
proﬁles [21].
A main feature of CKD is the dysfunction of multiple organs and
alterations in xenobiotic elimination pathways, however, the patho-
physiological mechanism underlying these changes are not fully elu-
cidated. In this study we demonstrated that a wide variety of uremic
toxins, belonging to several physico-chemical classes, inhibited renal
glucuronidation, most likely by reducing the reserve capacity of the
energy-generating OXPHOS system. Our results provide additional in-
sight into the widespread toxic effect of uremic solutes and depict a
novel pathway via which uremic toxins impede renal metabolicfunction and may have a clinically signiﬁcant impact on drug disposi-
tion in patients with CKD.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.09.006.
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